Scancell's melanoma data keeps widening the gap over standard care as phase III funding race heats up

Panmure Liberum holds its 'buy' rating and 32p target as FDA fast-track status adds regulatory momentum to compelling trial data. Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) shares rose 5.3% to 13.69p on Tuesday as the cancer immunotherapy developer delivered a double dose of positive news.